Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1997 Sep;105(Suppl 5):1061–1067. doi: 10.1289/ehp.97105s51061

Oncogenes and tumor-suppressor genes in mesothelioma--a synopsis.

J F Lechner 1, J Tesfaigzi 1, B I Gerwin 1
PMCID: PMC1470150  PMID: 9400701

Abstract

Invariably mesothelioma is diagnosed late in the development of the disease when treatment is no longer effective. Therefore, a key to reducing the mortality rate of this neoplasm is knowledge of the general sequence of genetic events between initiation of mesothelial cells and the emergence of the metastatic tumor cells. Unfortunately, relatively little is known about the early changes in the genesis of this disease. Of the known changes, the most frequent are in the tumor-suppressor genes p16INK4a and NF2 and possibly the SV40 virus large T-antigen oncogene. The molecular nature of the changes in these genes as well as other alterations are addressed in this overview.

Full text

PDF
1061

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams P. D., Kaelin W. G., Jr Transcriptional control by E2F. Semin Cancer Biol. 1995 Apr;6(2):99–108. doi: 10.1006/scbi.1995.0013. [DOI] [PubMed] [Google Scholar]
  2. Aerssens J., Guo C., Vermeesch J., Baens M., Browne D., Litt M., Van Den Berghe H., Marynen P. A physical map of the region spanning the chromosome 12 translocation breakpoint in a mesothelioma with a t(X;12)(q22;p13). Cytogenet Cell Genet. 1995;71(3):268–275. doi: 10.1159/000134125. [DOI] [PubMed] [Google Scholar]
  3. Amin K. M., Litzky L. A., Smythe W. R., Mooney A. M., Morris J. M., Mews D. J., Pass H. I., Kari C., Rodeck U., Rauscher F. J., 3rd Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol. 1995 Feb;146(2):344–356. [PMC free article] [PubMed] [Google Scholar]
  4. Bianchi A. B., Mitsunaga S. I., Cheng J. Q., Klein W. M., Jhanwar S. C., Seizinger B., Kley N., Klein-Szanto A. J., Testa J. R. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10854–10858. doi: 10.1073/pnas.92.24.10854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. BéruBé K. A., Quinlan T. R., Fung H., Magae J., Vacek P., Taatjes D. J., Mossman B. T. Apoptosis is observed in mesothelial cells after exposure to crocidolite asbestos. Am J Respir Cell Mol Biol. 1996 Jul;15(1):141–147. doi: 10.1165/ajrcmb.15.1.8679218. [DOI] [PubMed] [Google Scholar]
  6. Carbone M., Pass H. I., Rizzo P., Marinetti M., Di Muzio M., Mew D. J., Levine A. S., Procopio A. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene. 1994 Jun;9(6):1781–1790. [PubMed] [Google Scholar]
  7. Center R., Lukeis R., Dietzsch E., Gillespie M., Garson O. M. Molecular deletion of 9p sequences in non-small cell lung cancer and malignant mesothelioma. Genes Chromosomes Cancer. 1993 May;7(1):47–53. doi: 10.1002/gcc.2870070108. [DOI] [PubMed] [Google Scholar]
  8. Cheng J. Q., Jhanwar S. C., Klein W. M., Bell D. W., Lee W. C., Altomare D. A., Nobori T., Olopade O. I., Buckler A. J., Testa J. R. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994 Nov 1;54(21):5547–5551. [PubMed] [Google Scholar]
  9. Cheng J. Q., Jhanwar S. C., Lu Y. Y., Testa J. R. Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Res. 1993 Oct 15;53(20):4761–4763. [PubMed] [Google Scholar]
  10. Cicala C., Pompetti F., Carbone M. SV40 induces mesotheliomas in hamsters. Am J Pathol. 1993 May;142(5):1524–1533. [PMC free article] [PubMed] [Google Scholar]
  11. Coleman W. B., Tsongalis G. J. Multiple mechanisms account for genomic instability and molecular mutation in neoplastic transformation. Clin Chem. 1995 May;41(5):644–657. [PubMed] [Google Scholar]
  12. Cote R. J., Jhanwar S. C., Novick S., Pellicer A. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. Cancer Res. 1991 Oct 1;51(19):5410–5416. [PubMed] [Google Scholar]
  13. Cristaudo A., Vivaldi A., Sensales G., Guglielmi G., Ciancia E., Elisei R., Ottenga F. Molecular biology studies on mesothelioma tumor samples: preliminary data on H-ras, p21, and SV40. J Environ Pathol Toxicol Oncol. 1995;14(1):29–34. [PubMed] [Google Scholar]
  14. Dopp E., Saedler J., Stopper H., Weiss D. G., Schiffmann D. Mitotic disturbances and micronucleus induction in Syrian hamster embryo fibroblast cells caused by asbestos fibers. Environ Health Perspect. 1995 Mar;103(3):268–271. doi: 10.1289/ehp.95103268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Dorée M., Galas S. The cyclin-dependent protein kinases and the control of cell division. FASEB J. 1994 Nov;8(14):1114–1121. doi: 10.1096/fasebj.8.14.7958616. [DOI] [PubMed] [Google Scholar]
  16. Enoch T., Norbury C. Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends Biochem Sci. 1995 Oct;20(10):426–430. doi: 10.1016/s0968-0004(00)89093-3. [DOI] [PubMed] [Google Scholar]
  17. Flejter W. L., Li F. P., Antman K. H., Testa J. R. Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes. Genes Chromosomes Cancer. 1989 Nov;1(2):148–154. doi: 10.1002/gcc.2870010207. [DOI] [PubMed] [Google Scholar]
  18. Fujino S., Yokoyama A., Kohno N., Hiwada K. Interleukin 6 is an autocrine growth factor for normal human pleural mesothelial cells. Am J Respir Cell Mol Biol. 1996 Jun;14(6):508–515. doi: 10.1165/ajrcmb.14.6.8652179. [DOI] [PubMed] [Google Scholar]
  19. Funaki K., Everitt J., Bermudez E., Walker C. Trisomy of rat chromosome 1 associated with mesothelial cell transformation. Cancer Res. 1991 Aug 1;51(15):4059–4066. [PubMed] [Google Scholar]
  20. Gabrielson E. W., Gerwin B. I., Harris C. C., Roberts A. B., Sporn M. B., Lechner J. F. Stimulation of DNA synthesis in cultured primary human mesothelial cells by specific growth factors. FASEB J. 1988 Aug;2(11):2717–2721. doi: 10.1096/fasebj.2.11.3260881. [DOI] [PubMed] [Google Scholar]
  21. Garlepp M. J., Leong C. C. Biological and immunological aspects of malignant mesothelioma. Eur Respir J. 1995 Apr;8(4):643–650. [PubMed] [Google Scholar]
  22. Gerwin B. I. Cytokine signaling in mesothelial cells: receptor expression closes the autocrine loop. Am J Respir Cell Mol Biol. 1996 Jun;14(6):505–507. doi: 10.1165/ajrcmb.14.6.8652178. [DOI] [PubMed] [Google Scholar]
  23. Gerwin B. I., Lechner J. F., Reddel R. R., Roberts A. B., Robbins K. C., Gabrielson E. W., Harris C. C. Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res. 1987 Dec 1;47(23):6180–6184. [PubMed] [Google Scholar]
  24. Hagemeijer A., Versnel M. A., Van Drunen E., Moret M., Bouts M. J., van der Kwast T. H., Hoogsteden H. C. Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet. 1990 Jul 1;47(1):1–28. doi: 10.1016/0165-4608(90)90258-c. [DOI] [PubMed] [Google Scholar]
  25. Hall M., Bates S., Peters G. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene. 1995 Oct 19;11(8):1581–1588. [PubMed] [Google Scholar]
  26. Hansteen I. L., Hilt B., Lien J. T., Skaug V., Haugen A. Karyotypic changes in the preclinical and subsequent stages of malignant mesothelioma: a case report. Cancer Genet Cytogenet. 1993 Oct 15;70(2):94–98. doi: 10.1016/0165-4608(93)90174-k. [DOI] [PubMed] [Google Scholar]
  27. Harris C. C. p53 tumor suppressor gene: from the basic research laboratory to the clinic--an abridged historical perspective. Carcinogenesis. 1996 Jun;17(6):1187–1198. doi: 10.1093/carcin/17.6.1187. [DOI] [PubMed] [Google Scholar]
  28. Hirai H., Roussel M. F., Kato J. Y., Ashmun R. A., Sherr C. J. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol. 1995 May;15(5):2672–2681. doi: 10.1128/mcb.15.5.2672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hunter T., Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 1994 Nov 18;79(4):573–582. doi: 10.1016/0092-8674(94)90543-6. [DOI] [PubMed] [Google Scholar]
  30. Janssen Y. M., Heintz N. H., Marsh J. P., Borm P. J., Mossman B. T. Induction of c-fos and c-jun proto-oncogenes in target cells of the lung and pleura by carcinogenic fibers. Am J Respir Cell Mol Biol. 1994 Nov;11(5):522–530. doi: 10.1165/ajrcmb.11.5.7946382. [DOI] [PubMed] [Google Scholar]
  31. Kafiri G., Thomas D. M., Shepherd N. A., Krausz T., Lane D. P., Hall P. A. p53 expression is common in malignant mesothelioma. Histopathology. 1992 Oct;21(4):331–334. doi: 10.1111/j.1365-2559.1992.tb00403.x. [DOI] [PubMed] [Google Scholar]
  32. Kishimoto T. [The distribution of various type of oncogenes products in the tumor tissue of malignant mesothelioma]. Nihon Kyobu Shikkan Gakkai Zasshi. 1991 Sep;29(9):1168–1173. [PubMed] [Google Scholar]
  33. Kratzke R. A., Greatens T. M., Rubins J. B., Maddaus M. A., Niewoehner D. E., Niehans G. A., Geradts J. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res. 1996 Aug 1;56(15):3415–3420. [PubMed] [Google Scholar]
  34. Kratzke R. A., Otterson G. A., Lincoln C. E., Ewing S., Oie H., Geradts J., Kaye F. J. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst. 1995 Dec 20;87(24):1870–1875. doi: 10.1093/jnci/87.24.1870. [DOI] [PubMed] [Google Scholar]
  35. Lanfrancone L., Boraschi D., Ghiara P., Falini B., Grignani F., Peri G., Mantovani A., Pelicci P. G. Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor [CSF], granulocyte-monocyte-CSF, macrophage-CSF, interleukin-1 [IL-1], and IL-6) and are activated and stimulated to grow by IL-1. Blood. 1992 Dec 1;80(11):2835–2842. [PubMed] [Google Scholar]
  36. Langerak A. W., Dirks R. P., Versnel M. A. Splicing of the platelet-derived-growth-factor A-chain mRNA in human malignant mesothelioma cell lines and regulation of its expression. Eur J Biochem. 1992 Sep 15;208(3):589–596. doi: 10.1111/j.1432-1033.1992.tb17223.x. [DOI] [PubMed] [Google Scholar]
  37. Langerak A. W., Williamson K. A., Miyagawa K., Hagemeijer A., Versnel M. A., Hastie N. D. Expression of the Wilms' tumor gene WT1 in human malignant mesothelioma cell lines and relationship to platelet-derived growth factor A and insulin-like growth factor 2 expression. Genes Chromosomes Cancer. 1995 Feb;12(2):87–96. doi: 10.1002/gcc.2870120203. [DOI] [PubMed] [Google Scholar]
  38. Langerak A. W., van der Linden-van Beurden C. A., Versnel M. A. Regulation of differential expression of platelet-derived growth factor alpha- and beta-receptor mRNA in normal and malignant human mesothelial cell lines. Biochim Biophys Acta. 1996 Feb 7;1305(1-2):63–70. doi: 10.1016/0167-4781(95)00196-4. [DOI] [PubMed] [Google Scholar]
  39. Lauber B., Leuthold M., Schmitter D., Cano-Santos J., Waibel R., Stahel R. A. An autocrine mitogenic activity produced by a pleural human mesothelioma cell line. Int J Cancer. 1992 Apr 1;50(6):943–950. doi: 10.1002/ijc.2910500621. [DOI] [PubMed] [Google Scholar]
  40. Laveck M. A., Somers A. N., Moore L. L., Gerwin B. I., Lechner J. F. Dissimilar peptide growth factors can induce normal human mesothelial cell multiplication. In Vitro Cell Dev Biol. 1988 Nov;24(11):1077–1084. doi: 10.1007/BF02620808. [DOI] [PubMed] [Google Scholar]
  41. Lechner J. F., LaVeck M. A., Gerwin B. I., Matis E. A. Differential responses to growth factors by normal human mesothelial cultures from individual donors. J Cell Physiol. 1989 May;139(2):295–300. doi: 10.1002/jcp.1041390211. [DOI] [PubMed] [Google Scholar]
  42. Lechner J. F., Tokiwa T., LaVeck M., Benedict W. F., Banks-Schlegel S., Yeager H., Jr, Banerjee A., Harris C. C. Asbestos-associated chromosomal changes in human mesothelial cells. Proc Natl Acad Sci U S A. 1985 Jun;82(11):3884–3888. doi: 10.1073/pnas.82.11.3884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Lee I., Gould V. E., Radosevich J. A., Thor A., Ma Y. X., Schlom J., Rosen S. T. Immunohistochemical evaluation of ras oncogene expression in pulmonary and pleural neoplasms. Virchows Arch B Cell Pathol Incl Mol Pathol. 1987;53(3):146–152. doi: 10.1007/BF02890237. [DOI] [PubMed] [Google Scholar]
  44. Lee W. C., Balsara B., Liu Z., Jhanwar S. C., Testa J. R. Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma. Cancer Res. 1996 Oct 1;56(19):4297–4301. [PubMed] [Google Scholar]
  45. Libbus B. L., Craighead J. E. Chromosomal translocations with specific breakpoints in asbestos-induced rat mesotheliomas. Cancer Res. 1988 Nov 15;48(22):6455–6461. [PubMed] [Google Scholar]
  46. Lu Y. Y., Jhanwar S. C., Cheng J. Q., Testa J. R. Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma. Genes Chromosomes Cancer. 1994 Jan;9(1):76–80. doi: 10.1002/gcc.2870090114. [DOI] [PubMed] [Google Scholar]
  47. Maheswaran S., Englert C., Bennett P., Heinrich G., Haber D. A. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev. 1995 Sep 1;9(17):2143–2156. doi: 10.1101/gad.9.17.2143. [DOI] [PubMed] [Google Scholar]
  48. Mayall F. G., Goddard H., Gibbs A. R. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J Pathol. 1992 Dec;168(4):377–381. doi: 10.1002/path.1711680407. [DOI] [PubMed] [Google Scholar]
  49. Meloni A. M., Stephenson C. F., Li F. P., Sandberg A. A. del(6q) as a possible primary change in malignant mesothelioma. Cancer Genet Cytogenet. 1992 Mar;59(1):57–61. doi: 10.1016/0165-4608(92)90159-6. [DOI] [PubMed] [Google Scholar]
  50. Metcalf R. A., Welsh J. A., Bennett W. P., Seddon M. B., Lehman T. A., Pelin K., Linnainmaa K., Tammilehto L., Mattson K., Gerwin B. I. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res. 1992 May 1;52(9):2610–2615. [PubMed] [Google Scholar]
  51. Morgan W. F., Day J. P., Kaplan M. I., McGhee E. M., Limoli C. L. Genomic instability induced by ionizing radiation. Radiat Res. 1996 Sep;146(3):247–258. [PubMed] [Google Scholar]
  52. Olofsson K., Mark J. Specificity of asbestos-induced chromosomal aberrations in short-term cultured human mesothelial cells. Cancer Genet Cytogenet. 1989 Aug;41(1):33–39. doi: 10.1016/0165-4608(89)90105-2. [DOI] [PubMed] [Google Scholar]
  53. Park S., Schalling M., Bernard A., Maheswaran S., Shipley G. C., Roberts D., Fletcher J., Shipman R., Rheinwald J., Demetri G. The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet. 1993 Aug;4(4):415–420. doi: 10.1038/ng0893-415. [DOI] [PubMed] [Google Scholar]
  54. Pass H. I., Mew D. J., Carbone M., Matthews W. A., Donington J. S., Baserga R., Walker C. L., Resnicoff M., Steinberg S. M. Inhibition of hamster mesothelioma tumorigenesis by an antisense expression plasmid to the insulin-like growth factor-1 receptor. Cancer Res. 1996 Sep 1;56(17):4044–4048. [PubMed] [Google Scholar]
  55. Pass H. I., Stevens E. J., Oie H., Tsokos M. G., Abati A. D., Fetsch P. A., Mew D. J., Pogrebniak H. W., Matthews W. J. Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg. 1995 Apr;59(4):835–844. doi: 10.1016/0003-4975(95)00045-m. [DOI] [PubMed] [Google Scholar]
  56. Pelin K., Hirvonen A., Taavitsainen M., Linnainmaa K. Cytogenetic response to asbestos fibers in cultured human primary mesothelial cells from 10 different donors. Mutat Res. 1995 Apr;334(2):225–233. doi: 10.1016/0165-1161(95)90015-2. [DOI] [PubMed] [Google Scholar]
  57. Pines J. Cyclins, CDKs and cancer. Semin Cancer Biol. 1995 Apr;6(2):63–72. doi: 10.1006/scbi.1995.0009. [DOI] [PubMed] [Google Scholar]
  58. Popescu N. C., Chahinian A. P., DiPaolo J. A. Nonrandom chromosome alterations in human malignant mesothelioma. Cancer Res. 1988 Jan 1;48(1):142–147. [PubMed] [Google Scholar]
  59. Pyrhönen S., Tiainen M., Rautonen J., Tammilehto L., Laasonen A., Mattson K., Knuutila S. Comparison of DNA and karyotype ploidy in malignant mesothelioma. Cancer Genet Cytogenet. 1992 May;60(1):8–13. doi: 10.1016/0165-4608(92)90224-v. [DOI] [PubMed] [Google Scholar]
  60. Ramael M., Deblier I., Eerdekens C., Lemmens G., Jacobs W., Van Marck E. Immunohistochemical staining of ras oncogene product in neoplastic and non-neoplastic mesothelial tissues: immunoreactivity for N-ras and lack of immunohistochemical staining for Ha-ras and K-ras. J Pathol. 1993 Apr;169(4):421–424. doi: 10.1002/path.1711690406. [DOI] [PubMed] [Google Scholar]
  61. Ramael M., Segers K., Van Marck E. Differential immunohistochemical staining for retinoblastoma protein with the antibodies C15 and 1F8 in malignant mesothelioma. Pathol Res Pract. 1994 Feb;190(2):138–141. doi: 10.1016/S0344-0338(11)80703-X. [DOI] [PubMed] [Google Scholar]
  62. Roberts J. M., Koff A., Polyak K., Firpo E., Collins S., Ohtsubo M., Massagué J. Cyclins, Cdks, and cyclin kinase inhibitors. Cold Spring Harb Symp Quant Biol. 1994;59:31–38. doi: 10.1101/sqb.1994.059.01.006. [DOI] [PubMed] [Google Scholar]
  63. Segers K., Backhovens H., Singh S. K., De Voecht J., Ramael M., Van Broeckhoven C., Van Marck E. Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma. Virchows Arch. 1995;427(4):431–436. doi: 10.1007/BF00199393. [DOI] [PubMed] [Google Scholar]
  64. Sekido Y., Pass H. I., Bader S., Mew D. J., Christman M. F., Gazdar A. F., Minna J. D. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995 Mar 15;55(6):1227–1231. [PubMed] [Google Scholar]
  65. Spillare E. A., Okamoto A., Hagiwara K., Demetrick D. J., Serrano M., Beach D., Harris C. C. Suppression of growth in vitro and tumorigenicity in vivo of human carcinoma cell lines by transfected p16INK4. Mol Carcinog. 1996 May;16(1):53–60. doi: 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  66. Sánchez I., Dynlacht B. D. Transcriptional control of the cell cycle. Curr Opin Cell Biol. 1996 Jun;8(3):318–324. doi: 10.1016/s0955-0674(96)80004-4. [DOI] [PubMed] [Google Scholar]
  67. Taguchi T., Jhanwar S. C., Siegfried J. M., Keller S. M., Testa J. R. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res. 1993 Sep 15;53(18):4349–4355. [PubMed] [Google Scholar]
  68. Tiainen M., Hopman A., Moesker O., Ramaekers F., Wessman M., Laasonen A., Pyrhönen S., Tammilehto L., Mattson K., Knuutila S. Interphase cytogenetics on paraffin sections of malignant pleural mesothelioma. A comparison to conventional karyotyping and flow cytometric studies. Cancer Genet Cytogenet. 1992 Sep;62(2):171–179. doi: 10.1016/0165-4608(92)90258-a. [DOI] [PubMed] [Google Scholar]
  69. Tiainen M., Kere J., Tammilehto L., Mattson K., Knuutila S. Abnormalities of chromosomes 7 and 22 in human malignant pleural mesothelioma: correlation between Southern blot and cytogenetic analyses. Genes Chromosomes Cancer. 1992 Mar;4(2):176–182. doi: 10.1002/gcc.2870040212. [DOI] [PubMed] [Google Scholar]
  70. Ungar S., Van de Meeren A., Tammilehto L., Linnainmaa K., Mattson K., Gerwin B. I. High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines. Br J Cancer. 1996 Nov;74(10):1534–1540. doi: 10.1038/bjc.1996.585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Upadhyay S., Li G., Liu H., Chen Y. Q., Sarkar F. H., Kim H. R. bcl-2 suppresses expression of p21WAF1/CIP1 in breast epithelial cells. Cancer Res. 1995 Oct 15;55(20):4520–4524. [PubMed] [Google Scholar]
  72. Van der Meeren A., Seddon M. B., Betsholtz C. A., Lechner J. F., Gerwin B. I. Tumorigenic conversion of human mesothelial cells as a consequence of platelet-derived growth factor-A chain overexpression. Am J Respir Cell Mol Biol. 1993 Feb;8(2):214–221. doi: 10.1165/ajrcmb/8.2.214. [DOI] [PubMed] [Google Scholar]
  73. Versnel M. A., Claesson-Welsh L., Hammacher A., Bouts M. J., van der Kwast T. H., Eriksson A., Willemsen R., Weima S. M., Hoogsteden H. C., Hagemeijer A. Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene. 1991 Nov;6(11):2005–2011. [PubMed] [Google Scholar]
  74. Versnel M. A., Hagemeijer A., Bouts M. J., van der Kwast T. H., Hoogsteden H. C. Expression of c-sis (PDGF B-chain) and PDGF A-chain genes in ten human malignant mesothelioma cell lines derived from primary and metastatic tumors. Oncogene. 1988 Jun;2(6):601–605. [PubMed] [Google Scholar]
  75. Walker C., Bermudez E., Stewart W., Bonner J., Molloy C. J., Everitt J. Characterization of platelet-derived growth factor and platelet-derived growth factor receptor expression in asbestos-induced rat mesothelioma. Cancer Res. 1992 Jan 15;52(2):301–306. [PubMed] [Google Scholar]
  76. Walker C., Rutten F., Yuan X., Pass H., Mew D. M., Everitt J. Wilms' tumor suppressor gene expression in rat and human mesothelioma. Cancer Res. 1994 Jun 15;54(12):3101–3106. [PubMed] [Google Scholar]
  77. White E. Life, death, and the pursuit of apoptosis. Genes Dev. 1996 Jan 1;10(1):1–15. doi: 10.1101/gad.10.1.1. [DOI] [PubMed] [Google Scholar]
  78. Whyte P. The retinoblastoma protein and its relatives. Semin Cancer Biol. 1995 Apr;6(2):83–90. doi: 10.1006/scbi.1995.0011. [DOI] [PubMed] [Google Scholar]
  79. Xio S., Li D., Vijg J., Sugarbaker D. J., Corson J. M., Fletcher J. A. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene. 1995 Aug 3;11(3):511–515. [PubMed] [Google Scholar]
  80. Yegles M., Saint-Etienne L., Renier A., Janson X., Jaurand M. C. Induction of metaphase and anaphase/telophase abnormalities by asbestos fibers in rat pleural mesothelial cells in vitro. Am J Respir Cell Mol Biol. 1993 Aug;9(2):186–191. doi: 10.1165/ajrcmb/9.2.186. [DOI] [PubMed] [Google Scholar]
  81. Zeiger M. A., Gnarra J. R., Zbar B., Linehan W. M., Pass H. I. Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors. Genes Chromosomes Cancer. 1994 Sep;11(1):15–20. doi: 10.1002/gcc.2870110104. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES